Isocitrate dehydrogenase mutations in myeloid malignancies. - Wikidata - wikimedia - TriplyDB

Isocitrate dehydrogenase mutations in myeloid malignancies.

Isocitrate dehydrogenase mutations in myeloid malignancies.

http://www.wikidata.org/entity/Q37625630

about

The clinical significance of isocitrate dehydrogenase 2 in esophageal squamous cell carcinoma.The emerging role and targetability of the TCA cycle in cancer metabolism.Metabolic regulation of hematopoietic and leukemic stem/progenitor cells under homeostatic and stress conditions.Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1.Allosteric inhibitor remotely modulates the conformation of the orthestric pockets in mutant IDH2/R140Q.The role of metabolic enzymes in mesenchymal tumors and tumor syndromes: genetics, pathology, and molecular mechanisms.Targeting histone methyltransferase and demethylase in acute myeloid leukemia therapy.IDH1 Mutation Is an Independent Inferior Prognostic Indicator for Patients with Myelodysplastic Syndromes.Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia.A phase I study of CPI-613 in combination with high dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia.Antineoplastic chemotherapy in Jehovah's Witness patients with acute myelogenous leukemia refusing blood products - a matched pair analysis.Enasidenib: First Global Approval.The Role for Myc in Coordinating Glycolysis, Oxidative Phosphorylation, Glutaminolysis, and Fatty Acid Metabolism in Normal and Neoplastic Tissues.Personalizing initial therapy in acute myeloid leukemia: incorporating novel agents into clinical practice.Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia).Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group.Epigenetic dysregulation of TET2 in human glioblastoma.Biological Role and Therapeutic Potential of IDH Mutations in Cancer.Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations.Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter

P2860

Q37743530-51C9DF73-3F36-4900-86B6-42584AF19E28 Q38658458-FF65B71D-6DF6-4C7A-8F85-6975AF326184 Q39328089-DD6506A4-566B-4864-8223-387D03803A89 Q40319899-07ADEED7-6D34-4B31-BBC5-2B3AE32C9047 Q41530079-829A77FE-69A1-4F3C-8265-7422DB987558 Q46232869-AC11A08B-0B0B-40CF-B050-86C4B248BA8B Q47139135-1635F9F3-29AD-4A04-AFE7-FF03D68FE43E Q47728815-7C035118-05B6-451E-9F8B-3157730DC731 Q48533330-5A0B2C75-1C7D-451D-84CD-FC4B69E11494 Q48595265-1300DDFA-0218-428E-8C46-954093C408B3 Q48622093-65CB3E86-68C2-4FF1-927C-35173565CB28 Q50043852-40548E05-1FA9-4BA9-9716-E689F64CBBD3 Q50047415-67CD940B-1059-4D4E-97AB-7D0A9BB3D8AA Q50209891-6C11AB12-6C05-4D9B-9501-6803090108B9 Q52715807-323CD786-B3F6-4B39-8488-1448F8FE8B56 Q54956859-F790CB50-1736-4020-9714-AC5551E7AEE6 Q54964566-BF2CB554-B948-4ADE-9F25-D9816E1D6CCB Q55279705-09650BD5-A896-4821-9B67-16C567D53DD3 Q55287120-31A33841-DF29-410C-9645-F80686B59E0E Q55456962-4AA04667-59B4-47D3-8E62-E585A88FA4C3 Q55515402-EC80AB80-3920-4FD2-B30E-CCAE33218861 Q58766030-DA14F4B8-BB4A-4308-9447-88597F711AB0 Q59133388-916AC430-2699-4659-BC81-239AC723A251

P2860

Isocitrate dehydrogenase mutations in myeloid malignancies.

http://www.wikidata.org/entity/Q37625630

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 October 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Isocitrate dehydrogenase mutations in myeloid malignancies.

@en

Isocitrate dehydrogenase mutations in myeloid malignancies.

@nl

type

label

Isocitrate dehydrogenase mutations in myeloid malignancies.

@en

Isocitrate dehydrogenase mutations in myeloid malignancies.

@nl

prefLabel

Isocitrate dehydrogenase mutations in myeloid malignancies.

@en

Isocitrate dehydrogenase mutations in myeloid malignancies.

@nl

P1433

Q37625630-6C1930B0-2D2A-48CD-9D4A-FDA541B353ED

P1476

Q37625630-697D55D7-CA02-4FDA-B36F-EAEF856A50C9

P2093

Q37625630-4E84385B-EBCF-4836-9E26-73051530F4BC

Q37625630-6F0F2B73-0628-4862-BC95-6C176930CF66

Q37625630-B10840AB-929D-4011-BF45-165C3F264E0F

Q37625630-E8147BCF-7D12-47DB-956D-AC634CC3377B

Q37625630-F246BBE3-BC18-46F3-9065-6759128968A3

Q37625630-F487C546-E9CE-4BD8-8B56-FFBAF343C476

P275

Q37625630-D62A2834-1090-4059-9EC3-DFCCC41DA0BF

P2860

Q37625630-00B10D34-5860-4B01-AD9F-6D1D42004F59

Q37625630-05891C32-CD3E-4219-B9CA-3F7EF33A41D3

Q37625630-07B470F8-060E-412C-878C-DB85D10F6072

Q37625630-0A3AF867-A5E0-4A7F-9D76-90B8839BD11F

Q37625630-0B158EA2-1B57-49F2-923D-979638FDB74C

Q37625630-0C9644E6-7282-43A6-BC61-C4E27271E57A

Q37625630-0F938595-4A04-4FD7-B83E-B63046B023AC

Q37625630-13B0470E-C1A0-444F-8C56-163E4826DCF6

Q37625630-14BBEA4E-FD6F-44EB-8710-5708A4377C72

Q37625630-1A657A4B-2782-43F7-B5F7-7802BDF67846

P2888

Q37625630-8D57B8D4-59E3-4D7F-96C1-545DC040BA52

P304

Q37625630-8848EE83-B231-405A-9497-94FF3B6DA67C

P31

Q37625630-03A1CDCD-484B-486D-9844-A7DC2B6F5E1D

Q37625630-9A8696B6-976A-4032-89C8-8AF00FE566BA

P356

Q37625630-9782010F-6F6D-49FF-9A30-EACDC6DB9E2F

P433

Q37625630-F4600E5E-4423-4F1B-872C-68FB06655A05

P478

Q37625630-8012F27D-E666-4C22-9B10-E92D173C5D1C

P5008

Q37625630-7EE6EBE4-AA20-4600-8933-DBB2462970B5

P577

Q37625630-366CCB16-CBF5-40A1-81B1-A82D5F7377F1

Q37625630-FA1D267C-B9FD-4BF8-9A03-90D7D3B1FEC6

P6179

Q37625630-93736202-6FD2-407F-855D-C4EFCD3477A1

P698

Q37625630-101EFBA8-A2A7-4EDF-9819-25D4AF455627

P921

Q37625630-581EE80B-3A78-4B26-AF77-493798650B5F

Q37625630-64747815-5428-41E6-A961-381932AAFA4B

Q37625630-8304920B-6687-4B87-A8CC-A1212A96450F

P932

Q37625630-96ABFA3E-5378-44B6-A96A-DA4460A64CB1

P356

P1433

P1476

Isocitrate dehydrogenase mutations in myeloid malignancies.

@en

P2093

A T Fathi

http://www.w3.org/2001/XMLSchema#string

B C Medeiros

http://www.w3.org/2001/XMLSchema#string

C D DiNardo

http://www.w3.org/2001/XMLSchema#string

D A Pollyea

http://www.w3.org/2001/XMLSchema#string

R Swords

http://www.w3.org/2001/XMLSchema#string

S M Chan

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International

P2860

The epigenetic landscape of acute myeloid leukemia

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation

Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.

Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.

IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis.

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.

P2888

P304

272-281

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2016.275

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2016-10-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2017-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1000819053

http://www.w3.org/2001/XMLSchema#string

P698

27721426

http://www.w3.org/2001/XMLSchema#string

P921

acute myeloid leukemia

genetic variation

P932

5292675

http://www.w3.org/2001/XMLSchema#string